Melissa Alsina, MD

Melissa Alsina, MD cites recent data from ongoing studies as well as highlights remaining questions and unmet needs in the NDMM landscape.

An overview of prominent toxicities observed in patients receiving treatment for NDMM and standard countermeasures to address them, with a focus on neuropathy.

Dr Alsina describes key findings from the post-hoc analysis of the SWOG S0777 trial and explains how they inform treatment strategies for elderly patients.

A subject-matter-expert reviews updated efficacy results and subgroup analyses from the MAIA trial, evaluating D-Rd for transplant-not preferred NDMM.

Dr Alsina outlines criteria used in determining transplant eligibility and her approach to assessing standard risk versus high-risk in patients with NDMM.

Melissa Alsina, MD introduces a newly diagnosed multiple myeloma patient case, providing her perspective on the patient’s prognosis and treatment.